BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 22942238)

  • 1. Cullin7: a new gene involved in liver carcinogenesis related to metabolic syndrome.
    Paradis V; Albuquerque M; Mebarki M; Hernandez L; Zalinski S; Quentin S; Belghiti J; Soulier J; Bedossa P
    Gut; 2013 Jun; 62(6):911-9. PubMed ID: 22942238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular cytogenetic evaluation of virus-associated and non-viral hepatocellular carcinoma: analysis of 26 carcinomas and 12 concurrent dysplasias.
    Zondervan PE; Wink J; Alers JC; IJzermans JN; Schalm SW; de Man RA; van Dekken H
    J Pathol; 2000 Oct; 192(2):207-15. PubMed ID: 11004697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic evaluation of the dysplasia-carcinoma sequence in chronic viral liver disease: a detailed analysis of two cases and a review of the literature.
    van Dekken H; Wink J; Alers JC; de Man RA; IJzermans JN; Zondervan PE
    Acta Histochem; 2003; 105(1):29-41. PubMed ID: 12666986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatocellular carcinoma in HCV-infected patients awaiting liver transplantation: genes involved in tumor progression.
    Mas VR; Maluf DG; Stravitz R; Dumur CI; Clark B; Rodgers C; Ferreira-Gonzalez A; Fisher RA
    Liver Transpl; 2004 May; 10(5):607-20. PubMed ID: 15108252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deletion of chromosomes 9p and 17 associated with abnormal expression of p53, p16/MTS1 and p15/MTS2 gene protein in hepatocellular carcinomas.
    Shao J; Li Y; Li H; Wu Q; Hou J; Liew C
    Chin Med J (Engl); 2000 Sep; 113(9):817-22. PubMed ID: 11776078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted disruption of S100P suppresses tumor cell growth by down-regulation of cyclin D1 and CDK2 in human hepatocellular carcinoma.
    Kim JK; Jung KH; Noh JH; Eun JW; Bae HJ; Xie HJ; Ahn YM; Ryu JC; Park WS; Lee JY; Nam SW
    Int J Oncol; 2009 Dec; 35(6):1257-64. PubMed ID: 19885547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Marked genetic similarities between hepatitis B virus-positive and hepatitis C virus-positive hepatocellular carcinomas.
    Tornillo L; Carafa V; Richter J; Sauter G; Moch H; Minola E; Gambacorta M; Bianchi L; Vecchione R; Terracciano LM
    J Pathol; 2000 Nov; 192(3):307-12. PubMed ID: 11054713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of genetic changes in hepatocellular carcinoma by comparative genomic hybridization analysis: relationship to disease stage, tumor size, and cirrhosis.
    Wong N; Lai P; Lee SW; Fan S; Pang E; Liew CT; Sheng Z; Lau JW; Johnson PJ
    Am J Pathol; 1999 Jan; 154(1):37-43. PubMed ID: 9916916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Co-expression of XIAP and cyclin D1 complex correlates with a poor prognosis in patients with hepatocellular carcinoma.
    Che Y; Ye F; Xu R; Qing H; Wang X; Yin F; Cui M; Burstein D; Jiang B; Zhang DY
    Am J Pathol; 2012 May; 180(5):1798-807. PubMed ID: 22429965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of fetal promoters of insulinlike growth factors II gene in hepatitis C virus-related chronic hepatitis, cirrhosis, and hepatocellular carcinoma.
    Nardone G; Romano M; CalabrĂ² A; Pedone PV; de Sio I; Persico M; Budillon G; Bruni CB; Riccio A; Zarrilli R
    Hepatology; 1996 Jun; 23(6):1304-12. PubMed ID: 8675143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative analysis of apoptosis-related gene expression in hepatocellular carcinoma.
    Ikeguchi M; Hirooka Y; Kaibara N
    Cancer; 2002 Nov; 95(9):1938-45. PubMed ID: 12404288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis.
    Llovet JM; Chen Y; Wurmbach E; Roayaie S; Fiel MI; Schwartz M; Thung SN; Khitrov G; Zhang W; Villanueva A; Battiston C; Mazzaferro V; Bruix J; Waxman S; Friedman SL
    Gastroenterology; 2006 Dec; 131(6):1758-67. PubMed ID: 17087938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatic expression of the proliferative marker Ki-67 and p53 protein in HBV or HCV cirrhosis in relation to dysplastic liver cell changes and hepatocellular carcinoma.
    Koskinas J; Petraki K; Kavantzas N; Rapti I; Kountouras D; Hadziyannis S
    J Viral Hepat; 2005 Nov; 12(6):635-41. PubMed ID: 16255765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison study of the expressions of myristoylated alanine-rich C kinase substrate in hepatocellular carcinoma, liver cirrhosis, chronic hepatitis, and normal liver.
    Masaki T; Tokuda M; Yoshida S; Nakai S; Morishita A; Uchida N; Funaki T; Kita Y; Funakoshi F; Nonomura T; Himoto T; Deguchi A; Kimura Y; Izuishi K; Wakabayashi H; Usuki H; Yoshiji H; Watanabe S; Kurokohchi K; Kuriyama S
    Int J Oncol; 2005 Mar; 26(3):661-71. PubMed ID: 15703821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of p53 protein in liver and sera of patients with liver fibrosis, liver cirrhosis or hepatocellular carcinoma associated with chronic HCV infection.
    Attallah AM; Shiha GE; Ismail H; Mansy SE; El-Sherbiny R; El-Dosoky I
    Clin Biochem; 2009 Apr; 42(6):455-61. PubMed ID: 19063876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis.
    Paradis V; Zalinski S; Chelbi E; Guedj N; Degos F; Vilgrain V; Bedossa P; Belghiti J
    Hepatology; 2009 Mar; 49(3):851-9. PubMed ID: 19115377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Y chromosome loss and other genomic alterations in hepatocellular carcinoma cell lines analyzed by CGH and CGH array.
    Park SJ; Jeong SY; Kim HJ
    Cancer Genet Cytogenet; 2006 Apr; 166(1):56-64. PubMed ID: 16616112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genomic and immunophenotypical differences between hepatocellular carcinoma with and without cirrhosis.
    Tretiakova MS; Shabani-Rad MT; Guggisberg K; Hart J; Anders RA; Gao ZH
    Histopathology; 2010 May; 56(6):683-93. PubMed ID: 20546333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Steatohepatitic variant of hepatocellular carcinoma in the absence of metabolic syndrome or background steatosis: a clinical, pathological, and genetic study.
    Yeh MM; Liu Y; Torbenson M
    Hum Pathol; 2015 Nov; 46(11):1769-75. PubMed ID: 26410018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ursodiol use is possibly associated with lower incidence of hepatocellular carcinoma in hepatitis C virus-associated liver cirrhosis.
    Tarao K; Fujiyama S; Ohkawa S; Miyakawa K; Tamai S; Hirokawa S; Masaki T; Tanaka K
    Cancer Epidemiol Biomarkers Prev; 2005 Jan; 14(1):164-9. PubMed ID: 15668491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.